Olivier Clatz

Olivier Clatz

Olivier Clatz

Olivier Clatz is the French co-founder of AI medical diagnosis company Therapixel, creator of MammoScreen breast cancer screening and diagnosis tool. Prior to co-founding Therapixel, Clatz worked for six years as a research scientist at INRIA (National Institute for Research in Digital Science and Technology) based at the Sophia Antipolis technology park near Antibes, in the south of France. His later work with INRIA focused on exploiting machine learning algorithms for medical imaging processing. Prior to this, he was a research associate at Harvard Medical School, in the US. In 2006, he completed his PhD at INRIA on the concept of personalized medicine. Clatz also holds a PhD in philosophy from the Ecole des Mines de Paris, and a master's degree in applied mathematics from the Ecole Normale Supérieure Paris-Saclay. Currently, he works at the French Government’s Commissariat Générale pour l’Investissement managing the national program AI For Diagnostics. He left Therapixel in 2019.

Limited Reading

The rest of the content is only available if you are logged in.

Limited Reading

Gift This Article

The gift link can be opened by one recipient only.

You have 19 gift credits left this month

Your payment was not successful.

Please make sure you have entered your payment details correctly. Or try again in a few moments.

small logo

The discount code you entered is invalid

Please make sure you have entered your discount code correctly. Or try again in a few moments.

Download successful.

Your sample has been sent. Please check your email.

By accessing and using and all pages within the domain (the “Website”), You accept and agree to have read, understood, accepted and agreed to be bound by the Terms of Use and Privacy Policy in full. If you disagree with all or any part of these Terms of Use and Privacy Policy, please do not use or continue any further use of this website. You acknowledge that you are aware that this Website contains an archive of existing content as at 31 December 2021 and is not being actively managed. We are under no obligation to update the content on this Website and, accordingly, no new content or articles will be posted to the Website after 31 December 2021.